Lucie Bruijn serves as the therapeutic area biomarker lead for amyotrophic lateral sclerosis (ALS) at Novartis UK. Prior to joining Novartis, Bruijn had a long tenure at the ALS Association, serving as science director and chief scientist for 18 years. At ALSA, she was instrumental in the formation of many partnerships between ALS researchers, both in academia and industry, as well as establishing TREAT ALS, a translational research program to accelerate therapy development. Bruijn has been engaged in ALS since her postdoctoral work where she developed mouse models of ALS and focused on the gain of toxicity of mutant SOD1 and identified protein aggregation as an important contributor to disease.